利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.018 秒)

    Systems and methods for processing nucleic acid chromatograms
    2.
    发明申请
    Systems and methods for processing nucleic acid chromatograms 失效
    用于处理核酸色谱图的系统和方法

    公开(公告)号：US20060058969A1

    公开(公告)日：2006-03-16

    申请号：US10942538

    申请日：2004-09-15

    申请人： Guochun Liao ,  Jonathan Usuka ,  Gary Peltz

    发明人： Guochun Liao ,  Jonathan Usuka ,  Gary Peltz

    IPC分类号： G06F19/00

    CPC分类号： G06F19/22

    摘要： Computer systems, computer program products and methods for processing an input nucleic acid chromatogram having a plurality of substantially simultaneous traces. Each trace in the plurality of traces has a plurality of datapoints. Each respective datapoint in each of the plurality of datapoints represents a signal amplitude at a position in the trace corresponding to the respective datapoint. A first peak is identified in a first trace that is substantially overlapping a second peak in a second trace in the plurality of traces. The first peak is outputted to a first output homozygous representation and the second peak is outputted to a second output homozygous representation. The first output homozygous representation is a first homozygous sequence representation or a first homozygous nucleic acid chromatogram corresponding to the input nucleic acid chromatogram. The second output homozygous representation is a second homozygous sequence representation or second homozygous nucleic acid chromatogram of the input nucleic acid chromatogram.

    摘要翻译： 计算机系统，计算机程序产品和用于处理具有多个基本上同时的踪迹的输入核酸色谱图的方法。 多个迹线中的每个迹线具有多个数据点。 多个数据点中的每一个中的每个相应数据点表示对应于相应数据点的轨迹位置处的信号振幅。 在第一迹线中识别出第一峰值，其基本上与多个迹线中的第二迹线中的第二峰值重叠。 将第一峰值输出到第一输出纯合表示，并将第二峰值输出到第二输出纯合表示。 第一个输出纯合表达是对应于输入核酸色谱图的第一个纯合序列表示或第一个纯合的核酸色谱图。 第二个输出纯合表达是输入核酸色谱图的第二个纯合序列表示或第二个纯合的核酸色谱图。

    BIOMARKERS FOR DISTINGUISHING BENIGN, PRE-MALIGNANT, AND MALIGNANT PANCREATIC CYSTS
    4.
    发明申请
    BIOMARKERS FOR DISTINGUISHING BENIGN, PRE-MALIGNANT, AND MALIGNANT PANCREATIC CYSTS 审中-公开
    生物标记物，用于鉴别胆固醇，预防恶性肿瘤和恶性胰腺炎

    公开(公告)号：US20140236166A1

    公开(公告)日：2014-08-21

    申请号：US14180892

    申请日：2014-02-14

    申请人： Walter G. Park ,  Pankaj J. Pasricha ,  Gary Peltz ,  Anson Lowe

    发明人： Walter G. Park ,  Pankaj J. Pasricha ,  Gary Peltz ,  Anson Lowe

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57438 ,  G01N33/57488 ,  G01N2800/52 ,  G01N2800/56

    摘要： Methods for prognosis and diagnosis of pancreatic cysts are disclosed. In particular, the invention relates to the use of biomarkers from pancreatic cyst fluid to aid in the diagnosis, prognosis, and treatment of pancreatic cysts. More specifically, differential expression of certain metabolites, including glucose and kynurenine, and the protein, amphiregulin, is used to distinguish benign, pre-malignant, and malignant pancreatic cysts.

    摘要翻译： 公开了胰腺囊肿的预后和诊断方法。 特别地，本发明涉及来自胰腺囊肿液的生物标志物在胰腺囊肿诊断，预后和治疗中的应用。 更具体地，某些代谢物（包括葡萄糖和犬尿蛋白）和蛋白质双调蛋白的差异表达用于区分良性，恶性前恶性和恶性胰腺囊肿。

    Methods and Compositions for Treating or Preventing Narcotic Withdrawal Symptoms
    5.
    发明申请
    Methods and Compositions for Treating or Preventing Narcotic Withdrawal Symptoms 有权
    治疗或预防麻醉提取症状的方法和组成

    公开(公告)号：US20100144754A1

    公开(公告)日：2010-06-10

    申请号：US12631628

    申请日：2009-12-04

    申请人： Gary PELTZ ,  David CLARK ,  Lawrence CHU

    发明人： Gary PELTZ ,  David CLARK ,  Lawrence CHU

    IPC分类号： A61K31/4178 ,  A61K31/444 ,  A61K31/485 ,  A61K31/495 ,  A61P25/36

    CPC分类号： A61K31/4178 ,  A61K31/444 ,  A61K31/485 ,  A61K31/495 ,  A61K2300/00

    摘要： This invention provides methods and pharmaceutical compositions for preventing or treating physical dependence and/or withdrawal associated with narcotic use, in particular by modulating a 5-HT3 receptor. Using a computational genetic approach in mice, a gene conserved between mice and humans was identified as candidate as a modulator of physical dependence to morphine. Administration of compounds that modulate 5-HT3 receptors was found to control withdrawal from morphine in mice and humans.

    摘要翻译： 本发明提供了用于预防或治疗与麻醉药物使用相关的身体依赖和/或戒断的方法和药物组合物，特别是通过调节5-HT 3受体。 在小鼠中使用计算遗传学方法，将小鼠和人之间保守的基因鉴定为作为吗啡物理依赖的调节剂的候选物。 发现调节5-HT 3受体的化合物的给药可以控制小鼠和人类的吗啡戒断。

    Methods and compositions for treating or preventing narcotic withdrawal symptoms
    7.
    发明授权
    Methods and compositions for treating or preventing narcotic withdrawal symptoms 有权
    用于治疗或预防麻醉戒断症状的方法和组合物

    公开(公告)号：US09226918B2

    公开(公告)日：2016-01-05

    申请号：US12631628

    申请日：2009-12-04

    申请人： Gary Peltz ,  David Clark ,  Lawrence Chu

    发明人： Gary Peltz ,  David Clark ,  Lawrence Chu

    IPC分类号： A61K31/485 ,  A61K31/4178 ,  A61K31/444 ,  A61K31/495

    CPC分类号： A61K31/4178 ,  A61K31/444 ,  A61K31/485 ,  A61K31/495 ,  A61K2300/00

    摘要： This invention provides methods and pharmaceutical compositions for preventing or treating physical dependence and/or withdrawal associated with narcotic use, in particular by modulating a 5-HT3 receptor. Using a computational genetic approach in mice, a gene conserved between mice and humans was identified as candidate as a modulator of physical dependence to morphine. Administration of compounds that modulate 5-HT3 receptors was found to control withdrawal from morphine in mice and humans.

    摘要翻译： 本发明提供了用于预防或治疗与麻醉药物使用相关的身体依赖和/或戒断的方法和药物组合物，特别是通过调节5-HT 3受体。 在小鼠中使用计算遗传学方法，将小鼠和人之间保守的基因鉴定为作为吗啡物理依赖的调节剂的候选物。 发现调节5-HT 3受体的化合物的给药可以控制小鼠和人类的吗啡戒断。

    Associations of polymorphisms in the frbz gene in obesity and osteoporosis
    8.
    发明申请
    Associations of polymorphisms in the frbz gene in obesity and osteoporosis 有权
    肥胖和骨质疏松症中frbz基因多态性的关联

    公开(公告)号：US20060204965A1

    公开(公告)日：2006-09-14

    申请号：US10552641

    申请日：2004-04-20

    申请人： Russell Higuchi ,  Gary Peltz ,  Bonnie Fijal ,  Sunhee Ro ,  Jia Li

    发明人： Russell Higuchi ,  Gary Peltz ,  Bonnie Fijal ,  Sunhee Ro ,  Jia Li

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/156

    摘要： Methods and reagents for determining sequence variants present at the FRZB locus, which facilitate identifying individuals at risk for obesity and/or osteoporosis, are provided. In particular, methods for detecting an individual's risk for obesity and/or osteoporosis by detecting at least one polymorphism (e.g., at least one single nucleotide polymorphism) in the FRZB gene in a nucleic acid sample from the individual are provided. Related kits, arrays and systems are also described.

    摘要翻译： 提供了用于确定存在于FRZB基因座上的序列变体的方法和试剂，其有助于鉴定患有肥胖和/或骨质疏松症风险的个体。 特别地，提供了通过检测来自个体的核酸样品中的FRZB基因中的至少一个多态性（例如，至少一个单核苷酸多态性）来检测个体的肥胖和/或骨质疏松症的风险的方法。 还描述了相关工具包，阵列和系统。

    Polymorphic Plasminogen genes and uses thereof
    9.
    发明申请
    Polymorphic Plasminogen genes and uses thereof 审中-公开
    多形性纤溶酶原基因及其用途

    公开(公告)号：US20060051780A1

    公开(公告)日：2006-03-09

    申请号：US11108459

    申请日：2005-04-18

    申请人： Aimee Zaas ,  David Schwartz ,  Gary Peltz

    发明人： Aimee Zaas ,  David Schwartz ,  Gary Peltz

    IPC分类号： C12Q1/68 ,  G01N33/569 ,  G01N33/53

    CPC分类号： C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/172 ,  G01N2500/00

    摘要： The present invention relates to polymorphic Plasminogen genes and polypeptides. In particular, the present invention provides assays for the detection of Plasminogen polymorphisms and mutations associated with disease states and provides screening assays for the identification and use of compounds that alter Plasminogen activity and/or biological pathways involving Plasminogen.

    摘要翻译： 本发明涉及多形性纤溶酶原基因和多肽。 特别地，本发明提供了用于检测纤溶酶原多态性和与疾病状态相关的突变的测定，并提供了用于鉴定和使用改变纤溶酶原活性和/或涉及纤溶酶原的生物学途径的化合物的筛选测定。